GenMark Diagnostics (GNMK) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GenMark Diagnostics (GNMK) PT Lowered to $8 at Cowen; 'Bar is Low from Here'
February 28, 2018 6:43 AM ESTCowen lowered its price target on GenMark Diagnostics (NASDAQ: GNMK) to $8.00 (from $10.00) while maintaining an Outperform rating following Q4 results.
Analyst Doug Schenkel commented, "Q4 revenue was solid, but gross margins came up light. '18 revenue guidance was as expected, but... More
